Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -2.55%73 Days Payable is 3.69 as of Mar. 2026, which is 30% above its 10-year median of 2.83. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Pharma Aids ranks worse than 99.75% on this metric.
Pharma Aids's average Accounts Payable for the
three
months ended in Mar. 2026 was BDT3.4 Mil. Pharma Aids's Cost of Goods Sold for the
three
months ended in Mar. 2026 was BDT83.8 Mil.
Hence, Pharma Aids's Days Payable for the
three
months ended in Mar. 2026 was 3.69.
The historical rank and industry rank for Pharma Aids's Days Payable or its related term are showing as below:
DHA:PHARMAID'
s Days Payable Range Over the Past 10 Years
Min: 0.62 Med: 2.83 Max: 16.75
Current: 3.93
During the past 13 years, Pharma Aids's highest Days Payable was 16.75. The lowest was 0.62. And the median was 2.83.
DHA:PHARMAID's Days Payable is ranked worse than 99.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs DHA:PHARMAID: 3.93
Pharma Aids's Days Payable
increased
from Mar. 2025 (3.58) to Mar. 2026 (3.69).
It may suggest that Pharma Aidsdelayed paying its suppliers.
Pharma Aids Days Payable Related Terms
Pharma Aids Days Payable Historical Data
* Premium members only.
The historical data trend for Pharma Aids's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharma Aids's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharma Aids's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a Days Payable of 3.69 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharma Aids and its competitors. This is 30% above median its historical median of 2.83. Over the past decade, Pharma Aids' Days Payable has ranged from 0.62 to 16.75. According to the industry distribution chart, Pharma Aids ranks #793 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 99.7%.
Is Pharma Aids' Days Payable too high?
Pharma Aids' current Days Payable of 3.69 is 30% above median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 16.75. The Medical Devices & Instruments industry median Days Payable is 67.87. Pharma Aids' value of 3.69 is 94.6% below this industry median. Based on the distribution chart, Pharma Aids ranks #793 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #793 out of 795 companies for Days Payable. This places Pharma Aids in the lower half of its industry. The industry median Days Payable is 67.87. Pharma Aids' value of 3.69 is 94.6% below this benchmark. Historically, Pharma Aids' own Days Payable has ranged from 0.62 to 16.75 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 67.87, Pharma Aids has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current Days Payable of 3.69 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current Days Payable is 3.69, which is 30% above median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current Days Payable is 3.69, which is 30% above median its 10-year median of 2.83 and 94.6% below the Medical Devices & Instruments industry median of 67.87. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Days Payable is 3.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
Days Payable: 3.69 (30% above median its 10-year median of 2.83)
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
Industry Position: 94.6% below the Medical Devices & Instruments median (#793 of 795)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
